TELAXMAN - Laser Lithotripsy With Automatic Real-time Stone Recognition

Exploratory Feasibility Study of a Novel Laser System for Endoscopic Disintegration of Urinary Stones With Automatic Real-time Stone Recognition

Urolithiasis is an extremely common disease affecting about 12% of the world population with increasing tendency. Urinary stones are sediments that form in the kidney from crystals, such as calcium oxalate.

Currently, urological endoscopy with laser lithotripsy represents the leading and most frequently used method for the treatment of urinary stones of different localization, size and composition.

Surgical urology, including interventional stone treatment, is highly influenced by technology. With regard to fragmentation properties and effectiveness for all stone types Holmium:yttrium-aluminium-garnet (Ho:YAG) laser lithotripsy has become the standard technology to disintegrate urinary calculi.

In addition, other kinds of lasers are emerging, such as the thulium fiber laser (TFL); a new solid-state, diode-pumped laser that may provide urologists with increased options for stone treatment.

While urolithiasis treatment in general and laser lithotripsy in specific rarely goes along with major complications, recent studies have shown that there are possible indirect risks to the treatment with lasers, such as thermal damages to the urinary tract even at low-power settings if inadequate irrigation is applied. Sufficient irrigation is mandatory to perform safe Ho:YAG laser lithotripsy.

The RevoLix HTL+ automatic real-time stone detection module was developed to overcome these limitations and improve the safety of the patient with regard to potential thermal damages.

The objective of this clinical investigation is to assess the feasibility of stone recognition and disintegration with the RevoLix HTL+ in clinical conditions and to identify hypotheses to be used in future clinical investigations.

Study Overview

• Status: Completed
• Conditions: Lithotripsy, Laser
• Intervention / Treatment: Device: Laser lithotripsy with stone recognition; Other: Laser lithortripsy

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Freiburg, Germany, 79106
    • Universitatsklinikum Freiburg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject scheduled for laser lithotripsy
• Subject aged 18 or older
• Subject able to give consent
• Informed consent documented by signature

Exclusion Criteria:

• Subject pregnant or nursing
• Subject requiring emergency lithotripsy

• Contraindication for the surgical procedure:

  • Positive urine culture,
  • Unfit for general anesthesia,
  • Therapeutic anticoagulation, or systemic infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RevoLix HTL+; Laser lithotripsy using the RevoLix HTL+ with active stone recognition	Device: Laser lithotripsy with stone recognition; Application of Revolix HTL+ which features automatic real-time stone recognition
Other: Historic control group; Laser lithotripsy without active stone recognition	Other: Laser lithortripsy; Standard laser lithotripsy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual assessment of stone-free status;	Before retracting the ureteroscope, the surgeon will visualize the postoperative ureter along its entire length and record the stone-free status in the CRF, using the following scale: 0 - No residue; - Residual fragments ≤4mm; - Residual fragments >4mm Stone-free status is the state-of-the-art methodology for the description of the lithotripsy procedure, which is performed routinely at the investigation site. It does not require any additional invasive testing or procedures and it is performed intra-operatively.	During the procedure of laser lithotripsy, which should last for a maximum of 5 hours
Visual assessment of stone, tissue and endoscope recognition accuracy during laser lithotripsy	During the procedure, the surgeon will record every incidence of misrecognition by the RevoLix HTL+. Misrecognition is defined as inadequate laser pulse release on healthy tissue or endoscope.	During the procedure of laser lithotripsy, which should last for a maximum of 5 hours
Safety of device - assessment of device deficiencies	Safety of the device shall be evaluated by systematically reporting DDs and by monitoring the frequency and incidence of these events	During laser lithotripsy (duration of max 5 hours)
Safety of device - assessment of adverse events during the intervention	Safety of the device shall be evaluated by systematically reporting AEs and SAEs and by monitoring the frequency and incidence of these events	During laser lithotripsy (duration of max 5 hours)
Safety of device - assessment of adverse events during the follow up time	Safety of the device shall be evaluated by systematically reporting AEs and SAEs and by monitoring the frequency and incidence of these events	During the follow up time (up to 3 months)
New risk identification during the intervention	The practitioner will be asked to identify any new risks arising during laser lithotripsy using the investigational device	Within 12 hours after the intervention
New risk identification during the follow up time	The practitioner will be asked to identify any new risks related to the investigational device during the follow up time	During the follow up time (up to 3 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total laser emitted energy (J)	Total laser emitted energy is recorded by the laser system during each procedure. This data will be extracted after each procedure for the investigational arm and at the end of the investigation for the matching control arm.	Immediately (up to 1 hour) after the end of the intervention
Procedure duration (min)	Procedure duration will be recorded in the CRF as the time from endoscope insertion to retraction (Schnitt-Naht Zeit).	Immediately (up to 1 hour) after the end of the intervention
PULS classification of potential lesions visible via endoscopy immediately after the procedure	Before retracting the ureteroscope, the surgeon will visualize the postoperative ureter along its entire length and record PULS classification in the CRF. PULS is a 5 grades scale (0 - No lesion; 1 - Superficial mucosal lesion and/or significant mucosal oedema/hematoma; 2 - Submucosal lesion; 3 - Perforation with less than 50% partial transection; 4 - Perforation with more than 50% partial transection; 5 - Complete transection), in which lesions are graded independently of their location and extent. In case of multiple lesions, the most severe grading is applied.	During the procedure of laser lithotripsy, which should last for a maximum of 5 hours
Usability and workflow assessment (surgeon's questionnaire)	Immediately after his/her first procedure with RevoLix HTL+, the surgeon will fill in a questionnaire regarding the different aspects of the laser system.	Within 12 hours after the intervention

Collaborators and Investigators

• Sponsor: LISA Laser Products GmbH
• Investigators: Principal Investigator: Martin Schönthaler, Prof. Dr., Universitatsklinikum Freiburg

Study record dates

Study Major Dates

• Study Start (Actual): September 5, 2022
• Primary Completion (Actual): August 13, 2024
• Study Completion (Actual): August 13, 2024

Study Registration Dates

• First Submitted: August 9, 2022
• First Submitted That Met QC Criteria: August 12, 2022
• First Posted (Actual): August 15, 2022

Study Record Updates

• Last Update Posted (Actual): August 21, 2024
• Last Update Submitted That Met QC Criteria: August 20, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: TELAXMAN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No